A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of Baminercept, a Lymphotoxin-beta Receptor Fusion Protein, for the Treatment of Primary Sjogren's Syndrome (ASJ02)

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of Baminercept, a Lymphotoxin-beta Receptor Fusion Protein, for the Treatment of Primary Sjogren's Syndrome (ASJ02)

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Baminercept (Primary)
  • Indications Sjogren's syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DAIT
  • Most Recent Events

    • 16 Aug 2012 Planned End Date (Sep 2014) added as reported by ClinicalTrials.gov.
    • 16 Aug 2012 Actual initiation date (Jul 2012) added as reported by ClinicalTrials.gov.
    • 01 Jul 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top